<DOC>
	<DOCNO>NCT02409342</DOCNO>
	<brief_summary>This randomize , open-label study evaluate efficacy safety atezolizumab compare chemotherapy consist platinum agent ( cisplatin carboplatin per investigator discretion ) combine either pemetrexed ( non-squamous disease ) gemcitabine ( squamous disease ) program death-ligand 1 ( PD-L1 ) -selected participant chemotherapy-naive Stage IV Non-Squamous Squamous NSCLC .</brief_summary>
	<brief_title>A Study Atezolizumab ( MPDL3280A ) Compared With Platinum Agent ( Cisplatin Carboplatin ) + ( Pemetrexed Gemcitabine ) Participants With Stage IV Non-Squamous Squamous Non-Small Cell Lung Cancer ( NSCLC ) IMpower110</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm , Stage IV nonsquamous squamous NSCLC No prior treatment Stage IV nonsquamous squamous NSCLC , unless participant previously detect sensitize epidermal growth factor receptor ( EGFR ) mutation anaplastic lymphoma kinase ( ALK ) fusion oncogene Tumor PDL1 expression determine immunohistochemistry ( IHC ) assay archival tumor tissue tissue obtain screen Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) Adequate hematologic endorgan function Active untreated central nervous system ( CNS ) metastasis determine Computed Tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation Malignancies NSCLC within 5 year prior randomization , exception negligible risk metastasis death treat expect curative outcome Pregnant lactate woman History autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , drug induce pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest CT scan . History radiation pneumonitis radiation field ( fibrosis ) permit Positive test Human Immunodeficiency Virus ( HIV ) Active hepatitis B hepatitis C Prior treatment cluster differentiation ( CD ) 137 agonist immune checkpoint blockade therapy , anti PD1 , antiPDL1 therapeutic antibody Severe infection within 4 week prior randomization Significant history cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>